- Report
- February 2024
- 120 Pages
Global
From €4231EUR$4,750USD£3,610GBP
- Report
- April 2023
- 122 Pages
Global
From €4231EUR$4,750USD£3,610GBP
- Report
- June 2022
- 120 Pages
Global
From €4231EUR$4,750USD£3,610GBP
- Report
- December 2023
- 140 Pages
Global
From €3171EUR$3,560USD£2,706GBP
€3964EUR$4,450USD£3,382GBP
- Report
- September 2022
- 149 Pages
Global
From €3207EUR$3,600USD£2,736GBP
- Report
- January 2024
- 310 Pages
Global
€4449EUR$4,995USD£3,796GBP
- Report
- September 2022
- 109 Pages
Global
From €1782EUR$2,000USD£1,520GBP
The Orexin Receptor market is a subset of the Central Nervous System Drugs market. It is composed of drugs that target the Orexin Receptor, a protein found in the brain that is involved in the regulation of sleep and wakefulness. Orexin Receptor agonists are used to treat narcolepsy, a sleep disorder characterized by excessive daytime sleepiness. Orexin Receptor antagonists are used to treat insomnia, a sleep disorder characterized by difficulty falling asleep or staying asleep.
The Orexin Receptor market is a rapidly growing segment of the Central Nervous System Drugs market. It is expected to experience strong growth in the coming years due to the increasing prevalence of sleep disorders and the development of new drugs targeting the Orexin Receptor.
Some companies in the Orexin Receptor market include Merck, Pfizer, GlaxoSmithKline, Sanofi, and Takeda. Show Less Read more